Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 14/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.85 |
| ▸ | CDK9 | P50750 | 5/20 | 0.85 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.85 |
| ▸ | CDK2 | P24941 | 3/20 | 0.85 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22667343 | 0.88 | CCNT1 (1.00) | USP8CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL28848507 | 0.85 | USP8 (1.00) | USP8CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL22667340 | 0.85 | USP8 (1.00) | USP8CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL22667253 | 0.84 | USP8 (1.00) | USP8CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL22667334 | 0.84 | CCNT1 (1.00) | USP8CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL22667341 | 0.83 | USP8 (1.00) | USP8CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL22667342 | 0.81 | CCNT1 (0.85) | USP8CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL28848498 | 0.75 | USP8 (0.77) | USP8CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL22667339 | 0.74 | CCNT1 (0.70) | USP8CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL22667248 | 0.74 | USP8 (1.00) | USP8CCNT1CDK9CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020228513-A1 | NOVEL CDK9 INHIBITOR BASED ON BENZOPYRAN STRUCTURE, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国药科大学 | 2020-11-19 | — | — | WO | disclosed |